Pharmacologic treatments for covid-19 patients

Bamlanivimab+Etesevimab vs REGN-COV2

This comparison will not be updated. Last search date 14 Dec, 2022


Outpatients

Forest plots
(last update: 2023-01-27)

Summary of findings
(last update: 2022-11-22)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=496

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT05205759
MANTICO
Mazzaferri F, eLife, 2022
Full text
Full text
Commentary
Commentary
Commentary
Public/non profit

Bamlanivimab+Etesevimab

Bamlanivimab+Etesevimab

Sotrovimab

Casirivimab+Imdevimab (REGN-COV2)

Sotrovimab

Casirivimab+Imdevimab (REGN-COV2)

RCT Outpatients with confirmed COVID-19 (mild) treated at 20 centers in Italy. N=319
Some concerns
Details

Full description

NCT04790786
OPTIMISE-C19
McCreary E, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit

Bamlanivimab (LY-CoV555)

Bamlanivimab +etesevimab (LY-CoV555+LY-CoV016)

Bamlanivimab (LY-CoV555)

Casirivimab+Imdevimab (REGN-COV2)

Casirivimab+Imdevimab (REGN-COV2)

Bamlanivimab +etesevimab (LY-CoV555+LY-CoV016)

RCT Outpatients with confirmed COVID-19 (mild) treated at multiple ED or outpatient infusion centers or at home in the USA. N=1935
Some concerns
Details

Full description